OBJECTIVE: to assess the usefulness of the T-SPOT.TB™ interferon-gamma release assay (IGRA), as used in a regional hospital infectious diseases unit in Northwest England, for the diagnosis of active tuberculosis. DESIGN: Retrospective case series. RESULTS: T-SPOT.TB™ test was applied to a group of 64 patients, 20 of whom had tuberculosis (mostly extra-pulmonary tuberculosis). The T-SPOT.TB™ test had a sensitivity of 83.3% and a specificity of 75% for the diagnosis of active tuberculosis, compared with culture. A positive IGRA approximately doubled the pre-test probability of disease from 0.23 to 0.5. This doubling of probability was true regardless of HIV status, though for HIV+ patients the sensitivity was lower (sensitivity 66.7%, post test probability 0.4 for a positive IGRA result). When extrapolated to the local population the test was most useful for exclusion of disease; post test probability 0.006 (or 1 in 167) for a negative IGRA result. CONCLUSION: Although it can add weight to a clinical diagnosis, T-SPOT.TB™ assay is not reliable for the diagnosis of active tuberculosis in a real world setting where the test is often used in patients with smear negative or extra-pulmonary disease. The test is useful for ruling out disease in HIV negative patients.
OBJECTIVE: to assess the usefulness of the T-SPOT.TB™ interferon-gamma release assay (IGRA), as used in a regional hospital infectious diseases unit in Northwest England, for the diagnosis of active tuberculosis. DESIGN: Retrospective case series. RESULTS: T-SPOT.TB™ test was applied to a group of 64 patients, 20 of whom had tuberculosis (mostly extra-pulmonary tuberculosis). The T-SPOT.TB™ test had a sensitivity of 83.3% and a specificity of 75% for the diagnosis of active tuberculosis, compared with culture. A positive IGRA approximately doubled the pre-test probability of disease from 0.23 to 0.5. This doubling of probability was true regardless of HIV status, though for HIV+ patients the sensitivity was lower (sensitivity 66.7%, post test probability 0.4 for a positive IGRA result). When extrapolated to the local population the test was most useful for exclusion of disease; post test probability 0.006 (or 1 in 167) for a negative IGRA result. CONCLUSION: Although it can add weight to a clinical diagnosis, T-SPOT.TB™ assay is not reliable for the diagnosis of active tuberculosis in a real world setting where the test is often used in patients with smear negative or extra-pulmonary disease. The test is useful for ruling out disease in HIV negative patients.
Authors: Karen R Steingart; Megan Henry; Vivienne Ng; Philip C Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark Perkins; Mohamed Abdel Aziz; Madhukar Pai Journal: Lancet Infect Dis Date: 2006-09 Impact factor: 25.071
Authors: C J F Mundy; I Bates; W Nkhoma; K Floyd; G Kadewele; M Ngwira; A Khuwi; S B Squire; C F Gilks Journal: Trans R Soc Trop Med Hyg Date: 2003 Jul-Aug Impact factor: 2.184
Authors: Adithya Cattamanchi; Isaac Ssewenyana; J Lucian Davis; Laurence Huang; William Worodria; Saskia den Boon; Samuel Yoo; Alfred Andama; Philip C Hopewell; Huyen Cao Journal: BMC Infect Dis Date: 2010-03-20 Impact factor: 3.090
Authors: M Taegtmeyer; N J Beeching; J Scott; K Seddon; S Jamieson; S B Squire; H C Mwandumba; A R O Miller; P D O Davies; C M Parry Journal: Thorax Date: 2007-11-16 Impact factor: 9.139
Authors: Cynthia B E Chee; Suay H Gan; Kyi W Khinmar; Timothy M Barkham; Chwee K Koh; Shen Liang; Yee T Wang Journal: J Clin Microbiol Date: 2008-04-09 Impact factor: 5.948
Authors: Davinder P S Dosanjh; Timothy S C Hinks; John A Innes; Jonathan J Deeks; Geoffrey Pasvol; Sarah Hackforth; Hansa Varia; Kerry A Millington; Rubamalar Gunatheesan; Valerie Guyot-Revol; Ajit Lalvani Journal: Ann Intern Med Date: 2008-03-04 Impact factor: 25.391
Authors: Edward Raby; Maureen Moyo; Akash Devendra; Joseph Banda; Petra De Haas; Helen Ayles; Peter Godfrey-Faussett Journal: PLoS One Date: 2008-06-18 Impact factor: 3.240